Praluent and Sildenafil Interaction: What Prescribers and Patients Should Know

Why This Drug Combination Comes Up

Men with atherosclerotic cardiovascular disease (ASCVD) commonly face two concurrent treatment needs: aggressive LDL-C lowering and management of erectile dysfunction (ED). ED prevalence among men with coronary artery disease exceeds 60% according to a 2013 meta-analysis published in the Journal of Sexual Medicine [1]. Alirocumab, a PCSK9 inhibitor approved for heterozygous familial hypercholesterolemia and clinical ASCVD, is prescribed when statins alone fail to reach LDL-C targets [2]. Sildenafil remains the most widely prescribed PDE5 inhibitor for ED globally.

The Clinical Overlap

Patients on alirocumab are, by definition, at high cardiovascular risk. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab reduced major adverse cardiovascular events by 15% versus placebo in post-acute-coronary-syndrome patients [3]. These same patients carry elevated ED risk because endothelial dysfunction drives both conditions. A prescriber seeing this overlap needs a clear answer: do these two drugs interact?

Why the Question Persists

Drug interaction databases categorize queries by CYP enzyme overlap, transporter competition, and pharmacodynamic summation. Because alirocumab is a biologic, many automated databases simply return "no data" rather than "no interaction." That ambiguity drives clinician and patient uncertainty.

Pharmacokinetic Analysis: No Metabolic Overlap

Alirocumab and sildenafil are processed by entirely separate clearance systems. There is zero competition at the enzymatic level, zero shared transporter liability, and no protein-binding displacement concern between these agents.

Alirocumab Disposition

Alirocumab is a fully human IgG1 monoclonal antibody. Like all therapeutic antibodies, it undergoes target-mediated disposition (binding PCSK9 in plasma) and non-specific proteolytic catabolism through the reticuloendothelial system [2]. It does not enter hepatocytes for CYP-mediated oxidation. It is not a substrate, inhibitor, or inducer of any cytochrome P450 enzyme. The FDA-approved prescribing information for Praluent states that "population pharmacokinetic analyses indicated that no dose adjustments are necessary based on concomitant medications" [2].

Sildenafil Disposition

Sildenafil is a small-molecule PDE5 inhibitor metabolized primarily by CYP3A4, with a minor contribution from CYP2C9 [4]. Its major circulating metabolite, N-desmethyl sildenafil, retains approximately 50% of the parent compound's PDE5 inhibitory activity. Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole) increase sildenafil AUC by 200 to 1,000%, necessitating dose reduction [4]. Strong CYP3A4 inducers (rifampin, phenytoin) reduce exposure.

Why No Interaction Exists

A monoclonal antibody and a CYP3A4 substrate occupy non-overlapping pharmacokinetic space. Alirocumab cannot inhibit or induce CYP3A4 because it never enters the hepatocyte's metabolic machinery. It does not bind P-glycoprotein, OATP1B1, or BCRP. The FDA label for alirocumab confirms no clinically meaningful drug interactions have been identified in formal or population PK studies [2]. This is consistent with the broader class: evolocumab's prescribing information carries the same language [5].

Pharmacodynamic Considerations: Shared Vascular Territory

While there is no pharmacokinetic interaction, both drugs act on the vascular system. Understanding where their pharmacodynamic effects overlap helps clinicians manage the combination safely.

Blood Pressure Effects

Sildenafil produces a mean reduction in sitting systolic blood pressure of 8.4 mmHg and diastolic blood pressure of 5.5 mmHg, as reported in the original phase III data submitted to the FDA [4]. This effect is mediated through nitric oxide/cGMP-dependent smooth muscle relaxation. In patients already taking antihypertensives (common in the ASCVD population), additive hypotension is possible.

Alirocumab itself has no direct blood pressure effect. PCSK9 inhibition lowers circulating LDL-C through increased hepatic LDL receptor recycling [2]. No hemodynamic changes were observed in ODYSSEY OUTCOMES or ODYSSEY LONG TERM [3, 6].

The Nitrate Red Line

The absolute contraindication with sildenafil is concurrent nitrate therapy (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). Combined PDE5 inhibition and nitric oxide donation can produce life-threatening hypotension [4]. This has nothing to do with alirocumab, but it is the single most important safety check in any ASCVD patient being considered for sildenafil. The 2018 AHA/ACC cholesterol guideline and the 2024 ESC guidelines on chronic coronary syndromes both note that PCSK9 inhibitors do not alter the nitrate contraindication calculus [7, 8].

A Pre-Prescribing Safety Checklist

Before combining alirocumab and sildenafil, clinicians should confirm:

1. No concurrent nitrate use. Check the active medication list and confirm no as-needed nitroglycerin.
2. Stable blood pressure. Sitting BP should be documented at or above 90/60 mmHg before sildenafil initiation.
3. Statin interaction review. Most alirocumab patients co-administer atorvastatin or rosuvastatin. Atorvastatin is a CYP3A4 substrate that can modestly increase sildenafil exposure. Rosuvastatin (CYP2C9/2C19) has minimal interaction [9].
4. Alpha-blocker screening. Some ASCVD patients take doxazosin or tamsulosin for BPH. PDE5 inhibitors and alpha-blockers together increase orthostatic hypotension risk [4].

Statin-Sildenafil Interactions Deserve More Attention

Clinicians often focus on the alirocumab-sildenafil pair while overlooking the statin that sits between them. This is where real, measurable pharmacokinetic overlap exists.

Atorvastatin and Sildenafil

Both atorvastatin and sildenafil are CYP3A4 substrates. Co-administration produces a modest bidirectional increase in exposure. A pharmacokinetic study in healthy volunteers found that atorvastatin 80 mg increased sildenafil Cmax by approximately 22% [10]. The clinical significance is limited at standard atorvastatin doses (10 to 40 mg), but patients on high-intensity atorvastatin (80 mg) who also use sildenafil 100 mg may experience augmented PDE5 inhibition.

Rosuvastatin: The Cleaner Pairing

Rosuvastatin is metabolized primarily by CYP2C9 with minimal CYP3A4 involvement [9]. No pharmacokinetic interaction with sildenafil has been demonstrated. For patients requiring both high-intensity statin therapy and PDE5 inhibition, rosuvastatin may represent a pharmacokinetically simpler choice.

Ezetimibe Add-On

Some alirocumab patients also receive ezetimibe. Ezetimibe undergoes glucuronidation, not CYP oxidation, and has no interaction with sildenafil [11].

Dose Guidance for Combined Use

No dose adjustment of either alirocumab or sildenafil is required when the two are used together. Standard dosing applies to both.

Alirocumab Dosing

The recommended starting dose is 75 mg subcutaneously every 2 weeks. If LDL-C response is inadequate after 8 to 12 weeks, the dose may be increased to 150 mg every 2 weeks [2]. An alternative regimen of 300 mg every 4 weeks is also approved. None of these dose tiers are affected by sildenafil co-administration.

Sildenafil Dosing

For erectile dysfunction, sildenafil is typically initiated at 50 mg taken approximately 1 hour before sexual activity. The dose range is 25 to 100 mg, not to exceed once daily [4]. For patients on strong CYP3A4 inhibitors, a starting dose of 25 mg is recommended, but alirocumab is not a CYP3A4 inhibitor and does not trigger this reduction.

Timing Considerations

Alirocumab is administered every 2 weeks (or monthly). Sildenafil is taken on demand. There is no reason to separate administration times, though patients occasionally ask. The biologic's subcutaneous depot and the oral tablet's GI absorption pathway are completely independent.

Monitoring Recommendations

Monitoring for this combination is straightforward because it is additive to each drug's standalone monitoring, with one extra blood pressure check at the time of sildenafil initiation.

For Alirocumab

• Fasting lipid panel at baseline, 4 to 8 weeks after initiation or dose change, then every 3 to 12 months [2]
• Liver function tests are not routinely required per the FDA label, though many clinicians check ALT at baseline given background statin use [7]

For Sildenafil

• Blood pressure measurement before first dose and at follow-up
• Assessment for priapism risk factors (sickle cell disease, multiple myeloma, leukemia) [4]
• Visual disturbance screening (rare NAION association)

Combined Monitoring

The only additional step is verifying that the patient's resting blood pressure remains adequate (systolic greater than or equal to 90 mmHg) once both agents are on board. A single seated BP reading at the next follow-up visit is sufficient. No additional lab work is required beyond what each drug demands independently.

Special Populations

Hepatic Impairment

Alirocumab pharmacokinetics are unaffected by mild to moderate hepatic impairment. Severe hepatic impairment has not been studied [2]. Sildenafil clearance is reduced in hepatic impairment (Child-Pugh A and B), and a starting dose of 25 mg is recommended [4]. The interaction profile between the two drugs remains unchanged regardless of liver function.

Renal Impairment

Alirocumab is not renally cleared. Sildenafil pharmacokinetics are not significantly altered in mild to moderate renal impairment, though severe impairment (CrCl <30 mL/min) warrants a 25 mg starting dose [4]. Again, no interaction-specific dose modification is needed.

Older Adults

Men over 65 represent a large proportion of both alirocumab and sildenafil users. Sildenafil clearance is reduced by approximately 40% in healthy volunteers over age 65, leading to higher plasma concentrations [4]. This is a sildenafil-specific consideration, not an interaction effect. Standard alirocumab dosing applies regardless of age.

What About Other PCSK9 Inhibitors?

Evolocumab (Repatha) shares alirocumab's pharmacokinetic profile: monoclonal antibody, proteolytic clearance, no CYP involvement [5]. The FOURIER trial (N=27,564) confirmed cardiovascular benefit in statin-treated patients with ASCVD [12]. The interaction profile with sildenafil is identical to alirocumab's. No dose adjustment, no monitoring change.

Inclisiran (Leqvio), a small interfering RNA targeting hepatic PCSK9 mRNA, is also non-CYP-metabolized and does not interact with PDE5 inhibitors [13]. Its twice-yearly dosing schedule means even fewer theoretical windows for concern.

Patient Counseling Points

Patients asking about this combination need clear, jargon-free answers. Three messages matter most.

First, alirocumab and sildenafil do not interfere with each other. The cholesterol injection works through an entirely separate biological pathway from the ED pill.

Second, the real interaction danger is nitrates. If the patient uses nitroglycerin tablets or spray (even occasionally for chest pain), sildenafil is contraindicated. Patients must disclose all cardiac medications, including as-needed ones, before starting sildenafil [4].

Third, the statin matters more than the PCSK9 inhibitor for interaction purposes. Patients on high-dose atorvastatin should mention it to the prescriber managing sildenafil, as modest CYP3A4 competition exists [10].

A 2020 survey published in The Journal of Clinical Pharmacology found that 34% of men with cardiovascular disease did not disclose ED medication use to their cardiologist [14]. This communication gap, not a drug-drug interaction, represents the primary safety risk in this population.